Why the study?
The literature lacks an objective measure for diagnosing neuroleptic malignant syndrome, and concomitant toxicities or atypical presentations can distort the clinical picture.
Atypical neuroleptic malignant syndrome can present without fever in the setting of second-generation antipsychotic overdose, requiring prompt recognition and management.
Answers are grounded in this paper and cite their sources.
Afebrile NMS after SGA overdose warrants vigilance; this case leaves open revised diagnostic criteria.
Neuroleptic malignant syndrome (NMS) is a rare and life-threatening emergency. The condition is largely iatrogenic and is often precipitated by medications such as antipsychotics. First-generation antipsychotics are more likely to cause NMS than second-generation antipsychotics. The literature lacks an objective measure for NMS diagnosis. Instead, the diagnosis relies largely on the recognition of characteristic symptoms in the presence of an inciting medication. Additional challenges exist with concomitant disease processes and toxicities that may distort the clinical picture. Here, we report a case of a 44-year-old Caucasian man who presented with atypical NMS in the setting of quetiapine overdose. The patient remained uncharacteristically afebrile throughout his admission. Although the patient recovered, extended delays in identification and management can contribute to an increased risk of morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Hernandez et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: